Clinical Diagnosis and Treatment Recommendations for Immune Checkpoint Inhibitor-related Hematological Adverse Events / 中国肺癌杂志
Chinese Journal of Lung Cancer
; (12): 676-680, 2019.
Article
de Zh
| WPRIM
| ID: wpr-775572
Bibliothèque responsable:
WPRO
ABSTRACT
Immune checkpoint inhibitors are able to reactivate the immune system therefore enhance the anti-tumor effects. However, over-activated T cells may induce immune related adverse events (irAEs). Hematological irAEs are rarely reported, which mainly represent as mono-lineage cytopenia or pancytopenia, including autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), neutropenia and aplastic anemia, sometimes even lethal, such as hemophagocytic lymphohistiocytosis. The clinical manifestations of hematological irAEs will be summarized and recommendations of diagnosis and treatment are proposed.
Texte intégral:
1
Indice:
WPRIM
Type d'étude:
Diagnostic_studies
/
Guideline
langue:
Zh
Texte intégral:
Chinese Journal of Lung Cancer
Année:
2019
Type:
Article